Wall Street analysts expect DENTSPLY SIRONA Inc (NASDAQ:XRAY) to report $1.08 billion in sales for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for DENTSPLY SIRONA’s earnings. The highest sales estimate is $1.10 billion and the lowest is $1.07 billion. DENTSPLY SIRONA reported sales of $1.06 billion in the same quarter last year, which suggests a positive year over year growth rate of 1.9%. The firm is scheduled to report its next earnings report on Friday, March 6th.
According to Zacks, analysts expect that DENTSPLY SIRONA will report full-year sales of $3.99 billion for the current fiscal year, with estimates ranging from $3.96 billion to $4.02 billion. For the next financial year, analysts anticipate that the business will report sales of $4.11 billion, with estimates ranging from $4.07 billion to $4.13 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for DENTSPLY SIRONA.
DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.07. The firm had revenue of $962.10 million during the quarter, compared to analyst estimates of $940.38 million. DENTSPLY SIRONA had a net margin of 4.08% and a return on equity of 10.08%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.38 EPS.
A number of equities research analysts recently commented on XRAY shares. BidaskClub upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday. ValuEngine cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Finally, HC Wainwright restated a “hold” rating and set a $60.00 target price on shares of DENTSPLY SIRONA in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $56.08.
In related news, Director Michael C. Alfano sold 10,665 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $56.27, for a total transaction of $600,119.55. Following the sale, the director now owns 15,153 shares of the company’s stock, valued at approximately $852,659.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.62% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Rampart Investment Management Company LLC increased its position in shares of DENTSPLY SIRONA by 995.9% during the second quarter. Rampart Investment Management Company LLC now owns 29,831 shares of the medical instruments supplier’s stock worth $1,741,000 after acquiring an additional 27,109 shares in the last quarter. Man Group plc increased its holdings in DENTSPLY SIRONA by 160.5% during the 2nd quarter. Man Group plc now owns 930,798 shares of the medical instruments supplier’s stock worth $54,323,000 after purchasing an additional 573,519 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in DENTSPLY SIRONA by 8.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 272,347 shares of the medical instruments supplier’s stock worth $14,473,000 after purchasing an additional 20,103 shares in the last quarter. Bank of America Corp DE raised its stake in shares of DENTSPLY SIRONA by 2.0% in the 2nd quarter. Bank of America Corp DE now owns 993,418 shares of the medical instruments supplier’s stock valued at $57,975,000 after purchasing an additional 19,420 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of DENTSPLY SIRONA by 70.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 330,810 shares of the medical instruments supplier’s stock valued at $19,066,000 after purchasing an additional 137,163 shares during the period. Institutional investors and hedge funds own 94.35% of the company’s stock.
Shares of DENTSPLY SIRONA stock traded down $0.24 during trading on Thursday, reaching $58.05. 1,186,656 shares of the company were exchanged, compared to its average volume of 1,432,416. The company has a quick ratio of 1.39, a current ratio of 2.08 and a debt-to-equity ratio of 0.30. DENTSPLY SIRONA has a twelve month low of $34.93 and a twelve month high of $60.15. The business has a 50-day moving average price of $56.00 and a 200-day moving average price of $54.74. The firm has a market capitalization of $12.96 billion, a price-to-earnings ratio of 28.88, a P/E/G ratio of 2.04 and a beta of 0.95.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Featured Article: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.